Write a comment
A new COVID-19 treatment option is available for patients who are at the highest risk from the effects of the virus.
Treatments previously only available to people who were hospitalised with the virus are now being offered to eligible patients in the community.
In the last four weeks over 350 patients across Northern Ireland have received either the Neutralising Monoclonal Antibody treatment (nMABs) Sotrovimab, at a Trust Outpatient COVID-19 Treatment Service, or the oral antiviral medicine Molnupiravir, to take at home.
Speaking about the breakthrough Health Minister Robin Swann said: “It’s very encouraging to hear that patients in Northern Ireland are now benefiting from these ground-breaking drugs which have been approved by the Medicines Healthcare products Regulatory Agency (MHRA).
“Monoclonal antibodies and antivirals have been used by the health service since September of last year to treat patients who are hospitalised with severe COVID-19, and have been shown to improve survival and recovery time. The roll-out of these treatments to patients at highest risk in the community is a significant milestone in our battle against COVID-19 and will provide an additional layer of support for the most vulnerable in society.”
Chief Medical Officer, Professor Sir Michael McBride, said: “The vaccination programme remains our first line of defence against COVID-19 but these treatments have an important role in lowering the risk of severe illness and death and will also reduce the number of people who need to be admitted to hospital, thus helping to ease pressures on the health service over the challenging winter months.”
Chief Pharmaceutical Officer Cathy Harrison said: “These effective new treatments have been rolled out across Northern Ireland at pace and I want to commend clinical teams in our HSC Trusts who have worked exceptionally hard to identify and deliver treatment to patients at a very challenging time for the entire health service.
“With additional drugs due to become available shortly, following approval from the MHRA, we are maximising our ability to protect vulnerable patients and prevent them from serious illness.”
People who are eligible for these COVID-19 treatments are prioritised for PCR testing. If they have a positive lateral flow test, they should get a confirmatory PCR test. This is very important as a positive PCR result is required to access the new treatments.
Patients eligible for the latest treatments who receive a positive PCR test result will be contacted by a clinician from the health service to discuss what treatments could be suitable for them.
This may be from an unknown or withheld number.
If you don’t hear from your local Trust within a couple of days you can ask your GP practice to contact the Trust on your behalf.
If you test positive for COVID-19 and do not receive any text message about treatment, but feel you are eligible, you can contact your GP practice to discuss this.
More information for patients and the public about the roll-out of nMABs and antivirals is available at NI DIRECT
